Marshall Urist, EVP, Research & Investments at Royalty Pharma plc (RPRX), sold 46,666 shares at $39.85 ($1.9M) on 2022-05-16, disclosed to the SEC on 2022-05-16.
Open-market sale of $1.9M RPRX by EVP, Research & Investments. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $39.85 | 23,333 | $930K | 50.0% |
| 2 | $39.85 | 23,333 | $930K | 50.0% |
| Total | $39.85 avg | 46,666 | $1.9M | 100% |
| Filing → |
| RPRX | SELL | 2026-07-02 | $508K | — | Filing → |
| RPRX | SELL | 2026-06-25 | $502K | — | Filing → |
| RPRX | SELL | 2026-05-21 | $722K | — | Filing → |